

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Policy No:	PCN 220-2016
Date of Issue	October 2016
Review Date:	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p>Recommendations: The PCN recommends evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia in line with NICE TA394 (June 2016).</p> <p>Prescribing will be initiated and treatment continued by specialists with training in lipid management and notification of initiation and continuation of treatment will be via the Blueteq database.</p> <p>Evolocumab will be considered RED on the traffic light system</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> • NICE TA 394 (June 2016) Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia https://www.nice.org.uk/guidance/ta394/resources/evolocumab-for-treatingprimary-hypercholesterolaemia-and-mixed-dyslipidaemia-82602910172869 	
Date taken to Area Prescribing Committee	October 2016
Agreed by APC members	17th October 2016